Literature DB >> 27959316

Clostridium difficile Infection and Fecal Microbiota Transplant.

Alyssa Liubakka1, Byron P Vaughn1.   

Abstract

Clostridium difficile infection (CDI) is a major source of morbidity and mortality for hospitalized patients. Although most patients have a clinical response to existing antimicrobial therapies, recurrent infection develops in up to 30% of patients. Fecal microbiota transplant is a novel approach to this complex problem, with an efficacy rate of nearly 90% in the setting of multiple recurrent CDI. This review covers the current epidemiology of CDI (including toxigenic and nontoxigenic strains, risk factors for infection, and recurrent infection), methods of diagnosis, existing first-line therapies in CDI, the role of fecal microbiota transplant for multiple recurrent CDIs, and the potential use of fecal microbial transplant for patients with severe or refractory infection. ©2016 American Association of Critical-Care Nurses.

Entities:  

Keywords:  Clostridium difficile infection; fecal microbiota transplant; fecal transplant; recurrent C difficile infection

Mesh:

Year:  2016        PMID: 27959316      PMCID: PMC5666691          DOI: 10.4037/aacnacc2016703

Source DB:  PubMed          Journal:  AACN Adv Crit Care        ISSN: 1559-7768


  93 in total

1.  Risk factors for the development of Clostridium difficile-associated diarrhea during a hospital outbreak.

Authors:  A Thibault; M A Miller; C Gaese
Journal:  Infect Control Hosp Epidemiol       Date:  1991-06       Impact factor: 3.254

Review 2.  Diagnosis of Clostridium difficile infection by toxin detection kits: a systematic review.

Authors:  Tim Planche; Adamma Aghaizu; Richard Holliman; Peter Riley; Jan Poloniecki; Aodhán Breathnach; Sanjeev Krishna
Journal:  Lancet Infect Dis       Date:  2008-11-01       Impact factor: 25.071

3.  Clostridium difficile disease in a department of surgery. The significance of prophylactic antibiotics.

Authors:  J Yee; C M Dixon; A P McLean; J L Meakins
Journal:  Arch Surg       Date:  1991-02

Review 4.  Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections.

Authors:  Christina M Surawicz; Lawrence J Brandt; David G Binion; Ashwin N Ananthakrishnan; Scott R Curry; Peter H Gilligan; Lynne V McFarland; Mark Mellow; Brian S Zuckerbraun
Journal:  Am J Gastroenterol       Date:  2013-02-26       Impact factor: 10.864

5.  Impact of clinical symptoms on interpretation of diagnostic assays for Clostridium difficile infections.

Authors:  Erik R Dubberke; Zhuolin Han; Linda Bobo; Tiffany Hink; Brenda Lawrence; Susan Copper; Joan Hoppe-Bauer; Carey-Ann D Burnham; William Michael Dunne
Journal:  J Clin Microbiol       Date:  2011-06-22       Impact factor: 5.948

Review 6.  Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life.

Authors:  Sushrut Jangi; J Thomas Lamont
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-07       Impact factor: 2.839

Review 7.  Environmental interventions to control Clostridium difficile.

Authors:  Vivian G Loo
Journal:  Infect Dis Clin North Am       Date:  2015-01-05       Impact factor: 5.982

8.  Guidelines for environmental infection control in health-care facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC).

Authors:  Lynne Sehulster; Raymond Y W Chinn
Journal:  MMWR Recomm Rep       Date:  2003-06-06

9.  Clostridium difficile colitis: an efficient clinical approach to diagnosis.

Authors:  Y C Manabe; J M Vinetz; R D Moore; C Merz; P Charache; J G Bartlett
Journal:  Ann Intern Med       Date:  1995-12-01       Impact factor: 25.391

10.  Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy.

Authors:  Mark A Miller; Thomas Louie; Kathleen Mullane; Karl Weiss; Arnold Lentnek; Yoav Golan; Yin Kean; Pam Sears
Journal:  BMC Infect Dis       Date:  2013-03-25       Impact factor: 3.090

View more
  18 in total

Review 1.  From obesity through gut microbiota to cardiovascular diseases: a dangerous journey.

Authors:  Paolo Marzullo; Laura Di Renzo; Gabriella Pugliese; Martina De Siena; Luigi Barrea; Giovanna Muscogiuri; Annamaria Colao; Silvia Savastano
Journal:  Int J Obes Suppl       Date:  2020-07-20

Review 2.  The promise of the gut microbiome as part of individualized treatment strategies.

Authors:  Daniel A Schupack; Ruben A T Mars; Dayne H Voelker; Jithma P Abeykoon; Purna C Kashyap
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-08-27       Impact factor: 46.802

Review 3.  Advances in the diagnosis and treatment of Clostridium difficile infections.

Authors:  Zhong Peng; Lifen Ling; Charles W Stratton; Chunhui Li; Christopher R Polage; Bin Wu; Yi-Wei Tang
Journal:  Emerg Microbes Infect       Date:  2018-02-07       Impact factor: 7.163

Review 4.  Circulating Metabolites Originating from Gut Microbiota Control Endothelial Cell Function.

Authors:  Amedeo Amedei; Lucia Morbidelli
Journal:  Molecules       Date:  2019-11-05       Impact factor: 4.411

5.  Fecal microbiota transplantation for irritable bowel syndrome: An intervention for the 21st century.

Authors:  Magdy El-Salhy; Tanisa Patcharatrakul; Sutep Gonlachanvit
Journal:  World J Gastroenterol       Date:  2021-06-14       Impact factor: 5.742

Review 6.  Cost-Effectiveness of Fecal Microbiota Transplantation in the Treatment of Recurrent Clostridium Difficile Infection: A Literature Review.

Authors:  Leor T Arbel; Edmund Hsu; Keegan McNally
Journal:  Cureus       Date:  2017-08-23

Review 7.  The Relationship between Choline Bioavailability from Diet, Intestinal Microbiota Composition, and Its Modulation of Human Diseases.

Authors:  Natalia Arias; Silvia Arboleya; Joseph Allison; Aleksandra Kaliszewska; Sara G Higarza; Miguel Gueimonde; Jorge L Arias
Journal:  Nutrients       Date:  2020-08-05       Impact factor: 5.717

Review 8.  Management of Primary and Recurrent Clostridium difficile Infection: An Update.

Authors:  Jocelyn Chai; Christine H Lee
Journal:  Antibiotics (Basel)       Date:  2018-06-30

9.  Fecal microbiota transplantation for patients on antibiotic treatment with C. difficile infection history (GRAFT): Study protocol for a phase II, randomized, double-blind, placebo-controlled trial to prevent recurrent C. difficile infections.

Authors:  Ashley E Kates; Ilsa Gaulke; Travis De Wolfe; Michele Zimbric; Kendra Haight; Lauren Watson; Garret Suen; Kyungmann Kim; Nasia Safdar
Journal:  Contemp Clin Trials Commun       Date:  2020-05-19

10.  Bacteriophage endolysins as a potential weapon to combat Clostridioides difficile infection.

Authors:  Shakhinur Islam Mondal; Lorraine A Draper; R Paul Ross; Colin Hill
Journal:  Gut Microbes       Date:  2020-11-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.